Aktie 4743 ONENESS BIOTECH CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Oneness Biotech Co., Ltd.

Aktien

4743

TW0004743000

4743

Schlusskurs Taipei Exchange
Andere Börsenplätze
 00:00:00 30.04.2024 		% 5 Tage % 1. Jan.
158.5 TWD -0.31% Intraday Chart für Oneness Biotech Co., Ltd. +6.38% -18.51%
29.03. Oneness Biotech Co., Ltd. gibt die Einreichung eines Protokolls für eine klinische Phase-II-Studie bei der taiwanesischen FDA für die subkutane Injektionsformulierung vonFB825 bei Patienten mit mittelschwerer bis schwerer atopischer Dermatitis bekannt CI
11.03. Oneness Biotech Co., Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol to Taiwan FDA for Subcutaneous Injection Formulation ofFB825 in Patients with Moderate-To-Severe Atopic Dermatitis
Oneness Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol Forsubcutaneous Injection Formulation of FB825 in Patientswith Moderate-To-Severe Atopic Dermatitis
Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration
Oneness Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Oneness Biotech Co., Ltd. Announces Approval of FESPIXON
Oneness Submits Medical Device Registration Application of Bonvadis for Wound Care to the Thai Food and Drug Administration in Thailand
Oneness Biotech Co., Ltd. Submits 510(k) Application to the U.S. FDA to Expand the Intended Patient Population and Add Multiple Chronic Wound Indications for Bonvadis
Oneness Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Oneness Biotech Co., Ltd. Obtains Import License for Bonvadis, The Wound Care Topical Cream in South Africa
Oneness Biotech Co., Ltd. Announces Submission of Registration Application for Bonvadis, the Wound Care Topical Cream to the Drug Regulatory Authority of Pakistan
US FDA agrees to proceed with Phase 2 clinical trial for SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio
Oneness Biotech Co., Ltd. Receives Approval from Malaysia NPRA for FESPIXON, the New Drug in Treatment of Diabetic Footulcers
Oneness Biotech Co., Ltd. Announces the National Agency of Drug and Food Control Accepts the NDA Application of the Diabetic Foot Ulcer New Drug, Fespixon
Oneness Biotech Co., Ltd. Submits IND to US FDA for a Phase II Clinical Trial on the Broad-Spectrum Anti-SARS-CoV-2siRNA Co-Developed with Microbio
Oneness Biotech Co., Ltd. Announces Cash Dividend, Payable on July 21, 2023
Oneness Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Oneness and Microbio Co., Ltd. Announces the Phase 1 Clinical Trial Data of Sns812
Oneness Announces Bonvadis Cream for Scar Management Has Been Granted Import License in Europe
Oneness Receives Medical Devices Export License Approvals by TFDA on Bonvadis Topical Cream and Bonvadis Cream
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 4743 Aktie
  4. Nachrichten Oneness Biotech Co., Ltd.
  5. Andere Sprachen